✦ LIBER ✦

LONG-TERM CONTROL OF POLYCYTHEMIA RUBRA VERA WITH RECOMBINANT ALPHA INTERFERON

✍ Scribed by M. J. CLEMONS; Y. F. WILLIAMS; J. M. GOLDMAN; A. J. BARRETT

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 224 KB
Volume: 14
Category: Article
ISSN: 0278-0232
DOI: 10.1002/(sici)1099-1069(199603)14:1<37::aid-hon564>3.0.co;2-f

No coin nor oath required. For personal study only.

✦ Synopsis

The natural history of PRV is characterized by a prolonged period of myeloproliferation chiefly affecting the red cell series. It can be controlled by venesection and cytotoxic agents. In this case report the patient declined further 'standard' chemotherapy to control his disease and the use of relatively low doses of IFN-a was successful in our patient in controlling myeloproliferation and stabilizing the disease over a prolonged period. These results support the use of IFN-a, not only as a means of myelosuppression in PRV but also as an agent with the potential to prevent disease progression.

📜 SIMILAR VOLUMES

Relief of intractable pruritus in polycy

Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa

✍ Dr. Carlo Finelli; Luigi Gugliotta; Barbara Gamberi; Nicola Vianelli; Giuseppe V 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Following reports that recombinant interferon alfa (rlFNu), besides inducing clinical and hematologic remission in polycythemia Vera (PV), can also resolve intractable pruritus, we used rlFNu to treat 13 PV patients complaining of severe pruritus refractory to conventional treatment (venesection and

Polycythemia vera treated with recombina

Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone

✍ Massaro, Paolo; Foa, Paolo; Pomati, Mauro; LaTargia, Maria Luisa; Iurlo, Alessan 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 15 KB 👁 1 views

We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferonalpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations

Prediction of successful outcome in a ra

Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C

✍ Vandelli, Carmen; Renzo, Francesco; Braun, Hans Bertram; Tisminetzky, Sergio; Al 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

To evaluate the efficacy of a 12-month course of recombinant interferon alpha (IFN-␣2b), and to assess predictive factors of successful response to IFN therapy in chronic active hepatitis C (HCV CAH), 242 patients with histologically proven HCV CAH were assigned randomly to two groups, one treated w

Clinical significance of hepatic HCV RNA

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy

✍ Larghi, Alberto; Tagger, Alessandro; Crosignani, Andrea; Ribero, Maria Lisa; Bru 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Whether sustained biochemical response and absence of serum HCV RNA in the 6-12 months following suspension of interferon-␣ (IFN-␣) therapy reflect definitive viral clearance in patients with chronic hepatitis C virus (HCV) infection is controversial. To obtain more information on this topic, HCV RN

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views